Last updated 27 days ago
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)
390 patients around the world
Available in Argentina, Mexico
Merck Sharp & Dohme Corp.
21Research sites
390Patients around the world
This study is for people with
Solid tumors
Advanced tumors
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Sites
Perdriel 74, CABA, Buenos Aireshttps://www.hospitalbritanico.org.ar/
Calle 12 Nro 4756, Berazategui, Buenos Aires
Ramón Falcón 5206, CABA, Buenos Aireshttps://www.cemedic.com.ar/
Carrera 43 A No 7 -50A Oficina 304, Medellín, Antioquia
Cra. 38 BIS No. 5B2 - 04, Cali, Valle del Caucahttps://www.imbanaco.com/Investigacion/instituto-de-investigacion
Calle 1 #9-85, Bogotá D.Cwww.cancer.gov.co
Cra 15 # 14 – 91, Edificio San Jorge, Valledupar, César
Diagonal Sur - Nte 305, Colinas de Universidad, 89110 Tampico, Tamps., Mexico
Ejército Mexicano 3700, El Bajo, Chihuahua
Humboldt 302, ruta Independencia, Colonia Centro, Oaxaca de Juárez, Oaxaca. México. CP 68000
Av. Manuel Acuña #2543, Circunvalación Vallarta, Guadalajara, Jalisco
Calle Muzquiz #443 interior A, Col. Mitras Centro, Monterrey, Nuevo León, C.P. 64460
StudyMK-7339-002
SponsorMerck Sharp & Dohme Corp.
Study typeInterventional
Conditions
Solid tumors
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT03742895
